Therefore, the co-targeting of VEGF and of EGFR or HER2 does not seem to be relevant in terms of synergy or additivity, possibly due to negative interactions between signaling pathways, or pharmacodynamic interactions (lack of tumor vascularization, inhibition of the expression of one of the two receptors) [62,63]. The gene discussed is ERBB2; the disease is neoplasm.